journal article·2018-04

Tumor Cells‐Selective Bionic Nanodevice Exploiting Heparanase Combats Metastatic Breast Cancer

Tianqun Lang, Wei Ran, Xinyue Dong, Zhong Zheng, Yiran Liu, Qi Yin, Yaping Li

Advanced Functional Materials· Volume 28· Issue 17
Publisher page

Abstract

Abstract The clinical application of the cytotoxic chemotherapeutic agents in the treatment of metastatic breast cancer is limited by their poor selectivity to cancer cells. In this work, a bionic nanodevice consisting of the docetaxel (DTX)‐heparan sulfate (HS) conjugate (HS‐DTX) micelle with a red blood cells membrane (RBC) coating on its surface, termed as rHS‐DTX, is first constructed. It is found that the cytotoxicity of DTX is concealed by HS in human mammary epithelial Michigan Cancer Foundation (MCF)‐10A cells but restored in human mammary cancer MCF‐7 cells because HS is hydrolyzed by heparanase (Hpa), which is overexpressed only in MCF‐7 but not MCF‐10A cells. The RBC coating enhances the cellular uptake of HS‐DTX and endows it with the long circulating ability in blood. In the MCF‐7 metastatic breast cancer mice model, rHS‐DTX exhibits 6.35‐fold higher intratumor DTX accumulation than the free DTX injection and achieves a tumor inhibiting rate of 98.2% and a lung metastasis suppression rate of 99.6%. No severe toxicity is observed in the major organs and blood of mice treated with rHS‐DTX. In summary, rHS‐DTX can provide a promising strategy for targeting therapy of metastatic breast cancer by improving the tumor‐suppressing efficacy of DTX.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Proteoglycans and glycosaminoglycans research · Cancer Cells and Metastasis · Fibroblast Growth Factor Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Drug Research and Center of Pharmaceutics Shanghai Institute of Materia Medica Chinese Academy of Sciences 501 Haike Road Shanghai 201203 China

School of Pharmacy University of Chinese Academy of Sciences Beijing 100049 China

Funding

National Natural Science Foundation of China · Youth Innovation Promotion Association of the Chinese Academy of Sciences

References (25)

Show source-provided references
1. 10.3322/caac.2138710.3322/caac.21387 ↗
2. Gligorov J. · Nat. Rev. Clin. Oncol. · 2015 · 12 · 50810.1038/nrclinonc.2015.137 ↗
3. 10.1038/nrclinonc.2015.12310.1038/nrclinonc.2015.123 ↗
4. 10.1002/adfm.20160567910.1002/adfm.201605679 ↗
5. 10.1038/natrevmats.2016.7510.1038/natrevmats.2016.75 ↗
6. 10.1002/adfm.20170040310.1002/adfm.201700403 ↗
7. 10.1158/1078-0432.CCR-17-024210.1158/1078-0432.CCR-17-0242 ↗
8. Zhao B. B. · Exp. Hematol. · 2016 · 44 · 97510.1016/j.exphem.2016.06.249 ↗
9. 10.1016/j.matbio.2013.02.00610.1016/j.matbio.2013.02.006 ↗
10. 10.1002/smll.20160206610.1002/smll.201602066 ↗
11. 10.1038/nature1537310.1038/nature15373 ↗
12. 10.1002/adma.20160217310.1002/adma.201602173 ↗
13. 10.1002/adfm.20150478010.1002/adfm.201504780 ↗
14. 10.1021/acsnano.5b0104210.1021/acsnano.5b01042 ↗
15. 10.1002/adfm.20160338110.1002/adfm.201603381 ↗
16. 10.1007/s10549-014-3159-410.1007/s10549-014-3159-4 ↗
17. 10.1007/s12307-011-0082-710.1007/s12307-011-0082-7 ↗
18. 10.1016/j.jconrel.2010.02.02910.1016/j.jconrel.2010.02.029 ↗
19. 10.1021/acs.nanolett.7b0233010.1021/acs.nanolett.7b02330 ↗
20. 10.1002/adfm.20150128310.1002/adfm.201501283 ↗
21. 10.3892/mco.2017.128110.3892/mco.2017.1281 ↗
22. 10.1021/ar400300910.1021/ar4003009 ↗
23. 10.1038/ncb269010.1038/ncb2690 ↗
24. 10.1038/s41598-017-02591-610.1038/s41598-017-02591-6 ↗
25. 10.1093/annonc/mdv12910.1093/annonc/mdv129 ↗